The goal of this clinical trial (phase 2/phase 3) is to evaluate the efficacy and safety of
emetine administered orally for symptomatic Covid-19 patients in patients ages 30 years and
above. Participants will be asked to:
- Take Emetine 6mg orally for 10 consecutive days
- Be monitored by healthcare staff or self-monitor for daily vital signs and symptoms
- Undergo blood draws
Researchers will compare the control group given placebo medicine to assess if emetine
improved the symptoms of Covid-19.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
Bharatpur Hospital Chitwan Nepal Health Research Council Rutgers University Stony Brook University